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VIEWS AND REVIEWS
The promise of omega-3 against sudden 
unexpected death in epilepsy: until further 
notice, it remains innocent, until proven guilty
Promessa do ômega-3 contra a morte súbita em epilepsia: até segunda ordem, continua 
inocente, até que se prove o contrário
Fulvio Alexandre Scorza1, Antonio Carlos Lopes2, Roberta Monterazzo Cysneiros3, Ricardo Mario Arida4, 
Maurício Rocha e Silva5
Epilepsy is a common and very heterogeneous chronic 
neurological condition1,2. Often, it is still seen as a benign con-
dition in which individuals only have seizures. Unfortunately, 
the story is not as simple as it seems. Observational data 
over the years have shown that epilepsy is a malignant con-
dition that has a high rate of premature death compared with 
the general population3-5. Thus, sudden unexpected death 
in epilepsy (SUDEP) is the most important fatal complica-
tion of epilepsy6. In fact, it is responsible for 7.5 to 17% of all 
deaths in people with epilepsy and has an incidence among 
adults between 1:500 and 1:1,000 patient-years7. 
Recent research suggests that multiple risk factors may 
contribute for SUDEP, such as refractoriness of the epileptic 
condition, increased frequency of convulsive seizure, anti-
epileptic medication (polytherapy with antiepileptic drugs), 
longer duration of epilepsy, young age at onset, male sex, 
symptomatic cause, and lamotrigine therapy (in people with 
idiopathic generalized epilepsy)5,6,8-10. The cause or causes of 
SUDEP is/are still unknown, however experimental and clini-
cal research suggest that the main mechanism involved is 
autonomic dysregulation, i.e., respiratory and cardiovascular 
abnormalities during and after seizures6,9-11.
In this context, relevant putative mechanisms involved 
are cardiac arrhythmia, due to myocardial ischemia; electro-
lyte disturbances; arrhythmogenic drugs; or transmission of 
the epileptic activity via the autonomic nervous system to 
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ABSTRACT
The present paper highlighted the importance of the recommended levels of fish consumption or omega-3 supplementation in order to mini-
mize the frequency of seizures in people with uncontrolled epilepsy and, especially, to reduce the occurrence of sudden unexpected death in 
epilepsy (SUDEP).
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RESUMO
O presente trabalho destacou a importância dos níveis recomendados de consumo de peixe ou suplementação de ômega-3 com o intuito de 
minimizar a frequência de crises epilépticas em pessoas com epilepsia refratária e, especialmente, de reduzir a ocorrência de morte súbita 
inesperada em epilepsia (SUDEP).
Palavras-Chave: ômega-3, SUDEP, convulsões, epilepsia.
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the heart9,11-13. Actually, it is clear that SUDEP is mainly (but 
not exclusively) a problem for people with chronic uncon-
trolled epilepsy10, but our understanding of the best way to 
prevent is still incomplete. As SUDEP is probably a seizure-
related event, the successful seizure control is the best pre-
ventive measure1,9. Furthermore, others strategies have been 
suggested, which could be useful in reducing its risk10,14,15, al-
though strict evidence for their effectiveness is still lacking. 
Following this line of reasoning, the ultimate goal of research 
in SUDEP is to develop new methods for its prevention and 
actions other than medical and surgical therapies that could 
be very useful. Nutritional aspects, i.e., omega-3 fatty acids 
(omega-3 FAs), could have a prominent place in this sce-
nario, since promising research and evolving clinical experi-
ence support the idea that the omega-3 FAs have anti-seizure 
properties, as well as a possible effect in the prevention of 
cardiovascular abnormalities and a reduction of SUDEP oc-
currence14-16. Thus, a number of considerations could be put 
forward to explain these findings. 
Firstly, we must bear in mind that polyunsaturated FAs are 
present at high levels in the brain17. The four polyunsaturated 
FAs are designated eicosapentaenoic acid (EPA) and docosa-
hexaenoic acid (DHA), which are omega-3 FAs; and dihomo-
gammalinolenic (DGLA) and arachidonic acids (AA), which 
are n-6 FAs (omega-6), comprising over 10% (w/w) of the brain 
dry weight17,18. Fish and fish oil long-chain omega-3 FAs may 
interfere with certain nervous system diseases19. Furthermore, 
a diet rich in fish may be a good way to improve the develop-
ment of the brain and, undeniably, omega-3 FAs are impor-
tant for the treatment and prevention of cardiovascular and 
neurological diseases, including epilepsy16,19.
Concerning epilepsy, Spirer et al. suggested, in 1994, that 
omega-3 FAs may be used as a prophylactic to prevent fe-
brile seizures in susceptible children20. The authors postulat-
ed that since the most important substance mediating the fe-
brile response is interleukin-1 (IL-l), febrile convulsions could 
be prevented by reducing the concentration of secreted IL-l 
and supplementing the diet with omega-3 FAs20. In the same 
year, Yehuda et al. demonstrated anticonvulsant properties in 
a mixture of non-esterified alpha-linolenic and linoleic acids 
with a ratio of 1:4 (SR-3) in four rat models of epileptic sei-
zures21. In brief, these authors found that treatment with 
SR-3 (about 40 mg/kg intra-peritoneal) in a three-week prior 
to challenge was effective in each experimental model and 
caused up to a 22-fold increase in latency to major motor sei-
zures, up to 84% reduction in the number of rats with seizures, 
and up to 97% reduction in the duration of seizures21. 
Four years later, using the cortical stimulation seizure 
model in rats, Voskuyil et al.22 demonstrated a long-term 
modest anticonvulsant effect as a result of the administra-
tion of omega-3 FAs. Moreover, pharmacology studies show 
that omega-3 FAs applied extra-cellularly raise the stimula-
tory thresholds of CA1 neurons in hippocampal slices23. In a 
clinical study, it was reported on an open trial in which five 
patients took omega-3 FAs supplements24. In that study, a 
special spread, containing 65% omega-3 FAs, was added to 
the daily diet of five patients with epilepsy24. The patients 
consumed 5 g of this spread at every breakfast for 6 months, 
and all of them showed a marked reduction in both frequen-
cy and strength of epileptic seizures, suggesting that a dietary 
supplement containing omega-3 FAs may be beneficial for 
the suppression of some cases of epileptic seizures24. 
In the first randomized, placebo-controlled parallel trial 
of omega-3 FAs supplementation in 57 patients with refrac-
tory epilepsy, seizure frequency was reduced over the first 6 
weeks of treatment in the supplemented group, however this 
effect was not sustained over the 12-week total trial25. The au-
thors believe that the loss of effect following the initial six 
weeks is a result of omega-3 FAs preparations, doses, treat-
ment duration, and sample sizes25. Specifically, the research-
ers used in their study a total daily dose of approximately 
1.7 g omega-3 FAs (approximately 1 g EPA and 0.7 g DHA), 
but believe that higher doses and different omega-3 FAs ra-
tios should be tested25. 
Recently, our research was the first to demonstrate that a 
chronic treatment with omega-3 FAs promoted neuroprotec-
tion and positive plastic changes in the hippocampal forma-
tion of rats with epilepsy26,27. In addition, Taha et al. assessed 
the dose-dependent anticonvulsant effects of a fatty acid 
mixture with linoleic and alpha-linolenic acids in a 4:1 ratio 
(the SR-3 compound), and demonstrated that linoleic and al-
pha-linolenic polyunsaturated FAs in a 4:1 ratio raises ome-
ga-3 FAs composition of unesterified FAs in the brain and in-
creases resistance to pentylenetetrazol-induced seizures28. In 
2009, we have described the effectiveness of daily intake of a 
moderate amount of omega-3 FAs in a case of canine epilep-
sy29. Briefly, a two-year-old female Great Dane with history of 
idiopathic epilepsy initiated the pharmacological treatment 
under the supervision of a veterinary neurologist aimed at 
seizure control29. 
A trial therapy with phenobarbital (2.5 mg/kg, twice a day 
orally) failed to adequately control the seizures: after eight 
weeks of treatment, there remained two seizure episodes per 
month29. Typically, potassium bromide is used to supplement 
phenobarbital in refractory cases. However, in this case, it 
was decided to supplement the dog’s diet with moderate 
amounts of omega-3 FAs (oral, 2 g/day). The frequency of the 
epileptic seizures markedly decreased after 50 days of combi-
nation therapy with phenobarbital and omega-3 FAs. During 
the subsequent 18-month period, seizure frequency fell to 
one per three months, a reduction of about 85%29. In 2012, 
Yuen et al. evaluated a non-randomized open assessment of 
EPA supplementation, omega-3 FAs, in ten people with re-
fractory focal seizures30. The authors showed that six people 
had fewer seizures during the supplementation period com-
pared with baseline, and one other person had markedly 
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reduced seizure severity, suggesting that although the small 
number of participants and open nature of the study, inter-
pretation of the results is difficult, but a possible weak effect 
of EPA on seizures cannot be discounted30. 
From these results, we are totally in agreement with the 
proposal of Taha et al., therefore future clinical trials involv-
ing the omega-3 FAs should involve higher doses and longer 
periods of administration in order to definitively assess their 
possible anti-seizure effects16. We also must consider that the 
data presented so far confirm that omega-3 FAs reduce 
the frequency of epileptic seizures, promote neuroprotection 
and establish the safety of omega-3 FAs supplementation in 
people and animal models of refractory epilepsy14,15,26,27,29,31.
Concerning SUDEP, there is now great interest in ome-
ga-3 FAs supplementation for its prevention. As we know, 
the association between fish consumption and low rates of 
cardiovascular disease was studied nearly 40 years ago in 
the seafood diets consumed by Greenland Eskimos, Alaskan 
Natives, and Japanese people residing in fishing villages32. 
Actually, several studies have shown that omega-3 FAs have 
protective effects in preventing coronary heart disease, re-
ducing arrhythmias and thrombosis, lowering plasma tri-
glyceride levels, and reducing blood clotting tendency33. 
Furthermore, substantial evidence from epidemiological and 
case-control studies indicate that omega-3 FAs reduce the 
risk of cardiovascular mortality, with a potent effect on sud-
den cardiac death34,35. Thus, considering that omega-3 FAs 
per se are able to minimize cardiac arrhythmias and sudden 
cardiac deaths34,35, Yuen and Sander36 proposed the interest-
ing hypothesis that omega-3 FAs supplementation in people 
with refractory epilepsy may not only reduce seizures but 
also cardiac arrhythmias and hence SUDEP. Four years later, 
our research group reinforced this hypothesis37 from two ex-
periments conducted in our laboratory. Firstly, we evaluated 
the heart rate, in vivo (ECG) and isolated ex vivo preparation 
(Langendorf preparation) of rats with epilepsy38. Our results 
showed significant differences in the mean heart rate in vivo 
between the groups. In contrast, we did not find differences 
in the isolated ex vivo situation, suggesting a central nervous 
system modulation of the heart, which could explain SUDEP. 
Secondly, Scorza et al. (unpublished data) performed a simi-
lar set of experiments (heart rate in vivo and isolated ex vivo 
preparation) of rats with epilepsy before and after chronic 
omega-3 FAs supplementation. Their results showed differ-
ences in the mean heart rate in vivo, but surprisingly, none in 
heart rate could be observed in the isolated ex vivo condition.
On the whole, omega-3 FAs consumption improves vas-
cular and cardiac hemodynamics, triglycerides, autonomic 
control, inflammation, thrombosis, and arrhythmia and re-
duces risk of cardiac death35. In this context, Brazilian and in-
ternational guidelines have converged on consistent recom-
mendations for the general population to consume at least 
250 mg/day of long-chain omega-3 FAs or at least two serv-
ings/week of oily fish35. 
Finally, it is very important to emphasize that supplemen-
tation with omega-3 FAs for individuals with epilepsy is not 
a substitute for anticonvulsant medications. Thus, neurolo-
gists should recommend fish consumption for their patients, 
and government and public health agencies should imple-
ment strategies to improve attainment of the recommended 
levels of fish consumption or omega-3 FAs supplementation 
in order to minimize the frequency of seizures in people with 
uncontrolled epilepsy and mainly to reduce the occurrence 
of SUDEP in these individuals.
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